Table 1. Primary end-points of idiopathic pulmonary fibrosis clinical trials performed in the last 20 yrs
Noble et al. [11]FVC
Taniguchi et al. [12]VC
Daniels et al. [13]PFS#
King et al. [14]Survival
Raghu et al. [15]FVCDL,COPa,O2
King et al. [16]6MWT
Kubo et al. [17]Survival
Demedts et al. [18]VCDL,CO
Azuma et al. [8]Pa,O26MWT
Raghu et al. [9]PFS+
  • FVC: forced vital capacity; VC: vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; Pa,O2: arterial oxygen tension; 6MWT: 6-min walk test; PFS: progression-free survival. #: time to disease progression defined as decline in FVC (%) from baseline predicted FVC or death; : lowest arterial oxygen saturation measured by pulse oximetry during 6MWT; +: defined as ≥10% decline from baseline of predicted VC or an increase ≥5 mmHg in the alveolar–arterial oxygen tension difference at rest.